MeSH D013700 - giant cell arteritis
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Biogen | Tocilizumab | Tofidence | 2023-09-29 | |||
| Fresenius Kabi | Tocilizumab | Tyenne | 2023-09-15 | |||
| Genentech | Tocilizumab | Actemra | 2010-01-08 | |||
| Roche | Tocilizumab | RoActemra | 2009-01-15 |
Clinical Trials
Historical Success Rate
Phase 1
80%4/5
Phase 2
44%8/18
Phase 3
22%5/23
Approved: 2Overall Success rate: 8%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use